Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200000 participants
OBSERVATIONAL
2015-01-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Shanghai Cohort Study of Diabetic Eye Disease
NCT03665090
Shanghai Children and Adolescent Diabetes Eye Study
NCT03587948
Shanghai Beixinjing Diabetic Eyes Study
NCT03571217
The Diabetic Retinopathy Screening, Prevention and Control Program
NCT04240652
Community Screening Study of Diabetic Retinopathy in Tianjin in 2024
NCT06478407
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Screening, referral, follow-up and health management
Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Diabetics should not be able to move freely, clear-thinking and considered possible to cooperatively complete the ophthalmic examinations.
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Eye Disease Prevention and Treatment Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jiannan Huang
Shanghai Eye Disease Prevention and Treatment Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haidong Zou, MD,PhD
Role: STUDY_CHAIR
Shanghai Eye Disease Prevention and Treatment Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Eye Disease Prevention & Treatment Center
Shanghai, Jingan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zhu Xiaofeng, MM
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YFZX2018005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.